We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
- Authors
Kaira, Kyoichi; Naruse, Ichiro; Shimizu, Kimihiro; Asao, Takayuki
- Abstract
An 84-year-old male had a recurrence after surgical resection against Stage IIIA pulmonary adenocarcinoma and was treated with crizotinib due to harboring the anaplastic lymphoma kinase fusion gene. The patient exhibited crizotinib-induced interstitial lung disease (ILD), and alectinib was administered because of progressive disease. However, ILD appeared in both lungs again after alectinib treatment. This is the first case of ILD, resulting from alectinib administration after crizotinib-induced ILD. We should pay careful attention to patients who are treated with alectinib after crizotinib-induced ILD.
- Publication
Journal of Cancer Research & Therapeutics, 2020, Vol 16, Issue 3, p919
- ISSN
0973-1482
- Publication type
case study
- DOI
10.4103/jcrt.JCRT_985_15